Audioburst Search
|

Coming up next

Episode 23: Modulating the Signal

Novel Targets
|
1 year ago

Episode 17: Overcoming Immunotherapy Resistance

Novel Targets
|
3 years ago

CAR T: The Underdog Cancer Killer

GeekWire - Geared Up
|
1 year ago

Episode 19: Revolutionary Thinking Required

Novel Targets
|
2 years ago

Cultured Cells

Innovation Now
|
1 year ago

Interferon (Entry 652.PS10303)

Omnibus! With Ken Jennings and John Roderick
|
4 months ago

Hacking bacteria to fight cancer | Tal Danino

TED-Ed: Lessons Worth Sharing
|
4 months ago

Harnessing the Immune System to Diagnose and Treat Cancer

The Bio Report
|
8 months ago

066: Thomas Seyfried - Upending Traditional Cancer Treatment with Ketosis, Fasting, and Hyperbaric Oxygen

The Keto Answers Podcast
|
10 months ago

What is Cancer, and How Do We Treat It?

Healthcare Triage Podcast
|
1 year ago

Mayo Clinic Radio on Cancer: Pediatric cancer awareness

Mayo Clinic Radio on Cancer
|
3 years ago
Novel Targets

Automatic TRANSCRIPT

In this episode we take a look a look at how cytokines can be employed to modulate the tumour microenvironment in favourable ways. You'll hear various perspectives from numerous academic and industry experts who are active in research in this field, including Dr Mario Sznol (Yale), Dr James Gulley (NCI), Dr Adi Diab (MD Anderson), Dr Jonathan Zalevsky (Nektar Therapeutics), Dr Sanjeev Mariathasan (Genentech), Prof Tom Powles (Barts Cancer Institute), Dr Kunle Odunsi (Roswell Park), and Dr Renier Brentjens (Memorial Sloan Kettering). Some important topics that we will cover: - What are cytokines? - Why do they matter? - The good and bad effects they can induce on the tumour microenvironment (TME) - Interleukins - Transforming Growth Factor beta (TGFβ) - The increasingly important role for reverse translation research in helping to understand what's going on in the TME in order to improve rational future immuno-oncology (IO) combination approaches - Can we determine differences in responders and non-responders? - Novel approaches in clinical development, including CAR T cell therapies in solid tumours, and why they are different from previous approaches that were either too toxic or ineffective You can find more detailed information about the topics discussed in the show notes on https://noveltargets.com. Most of the interviews were conducted at recent AACR and ASCO meetings in 2018 and full transcripts of the individual interviews can be found on https://biotechstrategyblog.com. The music is by violinist and composer David Schulman. Listen to more at http://www.quietlifemotel.com © 2018 Blue Ice Publishing LLC. All Rights Reserved.